Гормональные факторы вирусассоциированного рака шейки матки
Ольга Николаевна Чуруксаева, О. Н. Асадчикова, Л. А. Коломиец et al. · CyberLeninK (CyberLeninka) · 2010
Objective: to study the urinary levels of estrogen metabolites as a diagnostic criterion in patients with cancer of the cervix uteri (CCU) associated with human papillomavirus (HPV) infection to provide a rationale for the use of pathogenetic therapy in the combination treatment of CCU. Subjects and methods. The study enrolled 26 patients with Stages I-IV CCU who were treated at the Department of Gynecology, Tomsk Research Institute of Oncology. The patients mean age was 45.6±1.3 years (range 24 to 72 years), the patients of reproductive age accounted for 50%. Tumor was staged in accordance with the FIGO classification. Genotyping was carried out on 12 oncotropic types, by estimating the viral load by polymerase chain reaction. Urinary estrogen metabolite levels were measured in all patients. Results. In the female patients, the urinary level of the metabolite 2-OHE1 responsible for normal cell growth was 8.95±2.9 ng/mg, which was significantly below the values in healthy women (19.7±1.2 ng/mg). The level of the metabolite 16α-OHE1 playing a key role in tumor cell transformation was 14.95±4.4 ng/mg, which did not differ significantly from the level in healthy women (15.2±2.4 ng/mg). There were no statistically significant differences in the levels of estrogen metabolites depending on tumor differentiation; but there was an inversely proportional relation to the stage of the process. Conclusion. The change in the estrogen metabolite ratio of 2-OHE1/16α-OHE1 toward a preponderance of the aggressive metabolite 16α-OHE1 contributes to the induction of the mechanisms of estrogen-dependent carcinogenesis. In this connection, it is expedient to use etiopathogenetic agents to block the key mechanisms of carcinogenesis in the combination treatment of CCU.
Cited by 1 works.